An analysis of the FDA’s MAUDE database finds that adverse event reports for oral appliances used to treat obstructive sleep apnea are increasing and shifting across categories. The finding underscores the need for continued post-market surveillance in dental sleep medicine devices. For clinicians and device makers, the key operational takeaway is that real-world safety signals appear to be accumulating rather than plateauing. The MAUDE-based view is also limited by reporting biases, but trend shifts typically prompt closer review by manufacturers and regulators. The report supports ongoing adverse event monitoring and may influence clinical practice patterns, including patient selection and follow-up protocols for oral appliance therapy.